Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail.
The appeals court ruling was issued unanimously by a conservative three-judge panel on Friday, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion.
The temporary decision was made in a case brought by Republican-led state of Louisiana claiming the FDA in adopting a 2023 rule – which allows mifepristone to be dispensed through the mail – had ignored the risks of serious adverse events posed by the drug, including sepsis and hemorrhaging.
Danco seeks Supreme Court
Categories: